Orhun Akdogan , Osman Sutcuoglu , Kadriye Bir Yucel , Ozan Yazici , Ahmet Ozet , Nuriye Ozdemir
{"title":"基于esmo临床获益量表评估胃肠系统癌症治疗方案及其与土耳其报销政策的关系","authors":"Orhun Akdogan , Osman Sutcuoglu , Kadriye Bir Yucel , Ozan Yazici , Ahmet Ozet , Nuriye Ozdemir","doi":"10.1016/j.jcpo.2025.100590","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Gastrointestinal system (GIS) cancers are a major global health challenge, with access to innovative therapies limited in resource-constrained settings. This study evaluates GIS cancer treatments in Turkey using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) and examines their reimbursement status.</div></div><div><h3>Methods</h3><div>Seventy-four treatment protocols were assessed using ESMO-MCBS, focusing on survival and quality-of-life benefits. Cost analyses of non-reimbursed protocols were conducted using the RxMedia Pharma 2024 database for a 70 kg patient.</div></div><div><h3>Results</h3><div>Only 31 % of the protocols were reimbursed, with nearly all curative regimens covered. In contrast, most metastatic treatments were non-reimbursed, despite significant clinical benefits. Non-reimbursed protocols with ESMO-MCBS scores ≥ 4 had 3-month costs ranging from $1000 to $10,000.</div></div><div><h3>Conclusion</h3><div>High-value therapies for GIS cancers remain largely inaccessible due to financial barriers. Incorporating ESMO-MCBS scores into reimbursement policies could improve access to effective treatments and align healthcare spending with clinical outcomes.</div></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"44 ","pages":"Article 100590"},"PeriodicalIF":2.0000,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Evaluation of treatment protocols based on the ESMO-magnitude of clinical benefit scale for gastrointestinal system cancers and their relationship with reimbursement policies in Turkey\",\"authors\":\"Orhun Akdogan , Osman Sutcuoglu , Kadriye Bir Yucel , Ozan Yazici , Ahmet Ozet , Nuriye Ozdemir\",\"doi\":\"10.1016/j.jcpo.2025.100590\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Gastrointestinal system (GIS) cancers are a major global health challenge, with access to innovative therapies limited in resource-constrained settings. This study evaluates GIS cancer treatments in Turkey using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) and examines their reimbursement status.</div></div><div><h3>Methods</h3><div>Seventy-four treatment protocols were assessed using ESMO-MCBS, focusing on survival and quality-of-life benefits. Cost analyses of non-reimbursed protocols were conducted using the RxMedia Pharma 2024 database for a 70 kg patient.</div></div><div><h3>Results</h3><div>Only 31 % of the protocols were reimbursed, with nearly all curative regimens covered. In contrast, most metastatic treatments were non-reimbursed, despite significant clinical benefits. Non-reimbursed protocols with ESMO-MCBS scores ≥ 4 had 3-month costs ranging from $1000 to $10,000.</div></div><div><h3>Conclusion</h3><div>High-value therapies for GIS cancers remain largely inaccessible due to financial barriers. Incorporating ESMO-MCBS scores into reimbursement policies could improve access to effective treatments and align healthcare spending with clinical outcomes.</div></div>\",\"PeriodicalId\":38212,\"journal\":{\"name\":\"Journal of Cancer Policy\",\"volume\":\"44 \",\"pages\":\"Article 100590\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2025-05-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Cancer Policy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2213538325000347\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"HEALTH POLICY & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer Policy","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213538325000347","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH POLICY & SERVICES","Score":null,"Total":0}
Evaluation of treatment protocols based on the ESMO-magnitude of clinical benefit scale for gastrointestinal system cancers and their relationship with reimbursement policies in Turkey
Background
Gastrointestinal system (GIS) cancers are a major global health challenge, with access to innovative therapies limited in resource-constrained settings. This study evaluates GIS cancer treatments in Turkey using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) and examines their reimbursement status.
Methods
Seventy-four treatment protocols were assessed using ESMO-MCBS, focusing on survival and quality-of-life benefits. Cost analyses of non-reimbursed protocols were conducted using the RxMedia Pharma 2024 database for a 70 kg patient.
Results
Only 31 % of the protocols were reimbursed, with nearly all curative regimens covered. In contrast, most metastatic treatments were non-reimbursed, despite significant clinical benefits. Non-reimbursed protocols with ESMO-MCBS scores ≥ 4 had 3-month costs ranging from $1000 to $10,000.
Conclusion
High-value therapies for GIS cancers remain largely inaccessible due to financial barriers. Incorporating ESMO-MCBS scores into reimbursement policies could improve access to effective treatments and align healthcare spending with clinical outcomes.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
